@article {7703,
	title = {Romiplostim for secondary thrombocytopenia following allogeneic stem cell transplantation in children.},
	journal = {Int J Hematol},
	volume = {102},
	year = {2015},
	month = {2015 Nov},
	pages = {626-32},
	abstract = {<p>The outcome of romiplostim for secondary failure of platelet recovery (SFPR) was investigated in children who had undergone hematopoietic stem cell transplantation (HSCT). Seven transfusion-dependent pediatric patients (median age 11~years), with platelet counts below 10~{\texttimes}~10(9)/L, received four weekly doses of subcutaneous romiplostim to treat SFPR developed after HSCT. All patients, except one (patient 4), became platelet transfusion-independent in the second week from the beginning of treatment and no patient needed to discontinue drug treatment because of adverse events. Romiplostim could represent a beneficial first-line treatment, but further studies are required.</p>},
	issn = {1865-3774},
	doi = {10.1007/s12185-015-1821-1},
	author = {Maximova, Natalia and Zanon, D and Rovere, F and Maestro, A and Schillani, G and Paparazzo, R}
}
@article {1910,
	title = {Treatment with pamidronate for osteoporosis complicating long-term intestinal failure.},
	journal = {J Pediatr Gastroenterol Nutr},
	volume = {55},
	year = {2012},
	month = {2012 Nov},
	pages = {615-8},
	abstract = {<p>Long-term home parenteral nutrition (PN) is a potential risk for developing osteoporosis. Various attempts have been made to treat bone disease both by modifying the composition of PN and by administering hormones, such as calcitonin, parathyroid hormone, and sexual hormones. Bisphosphonates are recognized as a medication useful for the treatment of several bone disorders associated with excessive reabsorption. Nevertheless, there have been no paediatric studies on bisphosphonates use for intestinal failure-associated bone disease. Our study includes 6 paediatric patients receiving extremely long-term home PN (at least 3 years) who showed radiological and clinical signs of osteoporosis. Diagnosis of bone disease was made after a median period of 127.5 PN months. Treatment consisted in 2 cycles of intravenous pamidronate, 30 mg/m once per month for 6 months consecutively. They all showed a significant improvement in bone mineral density, evaluated after 6 and 12 months of pamidronate treatment. In our sample anthropometrical variables (weight, height, and body mass index) are not related with the z-score trend. Our patients had normal levels of calcium, phosphorus, and vitamin D, and proper nutrient intake. At the last follow-up, dual-energy x-ray absorptiometry scan showed that no patients had a z-score lower than -2.5; moreover, nobody developed bone fractures during the 108-month follow-up. The patients did not have any prominent adverse effect. Finally, in our experience, pamidronate is effective for improving bone mineral density and safe in patients with intestinal failure-associated bone disease.</p>},
	keywords = {Absorptiometry, Photon, Adolescent, Bone Density, Bone Density Conservation Agents, Child, Child, Preschool, Diphosphonates, Female, Humans, Intestinal Diseases, Male, Osteoporosis, Parenteral Nutrition, Home},
	issn = {1536-4801},
	doi = {10.1097/MPG.0b013e31825f1c7d},
	author = {Pastore, S and Londero, M and Barbieri, F and Di Leo, G and Paparazzo, R and Ventura, A}
}
